KalVista Pharmaceuticals Overview
- Year Founded
-
2011
- Status
-
Acquired/Merged
- Employees
-
270
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$1.6B
- Investors
-
1
KalVista Pharmaceuticals General Information
Description
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
Contact Information
Website
www.kalvista.com(Operating Subsidiary)
Corporate Office
- 200 Crossing Boulevard
- Framingham, MA 01702
- United States
Corporate Office
- 200 Crossing Boulevard
- Framingham, MA 01702
- United States
KalVista Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 14. Merger/Acquisition | 11-Jun-2026 | $1.6B | Completed | Generating Revenue | ||
| 13. PIPE | 10-Jul-2025 | Completed | Generating Revenue | |||
| 12. PIPE | 04-Nov-2024 | Completed | Generating Revenue | |||
| 11. 2PO | 04-Nov-2024 | Completed | Generating Revenue | |||
| 10. 2PO | 15-Feb-2024 | Completed | Generating Revenue | |||
| 9. PIPE | 11-Aug-2023 | Completed | Generating Revenue | |||
| 8. Secondary Transaction - Private | 20-Aug-2019 | Completed | Generating Revenue | |||
| 7. Secondary Transaction - Open Market | Completed | Generating Revenue | ||||
| 6. Secondary Transaction - Private | 12-Oct-2017 | $7.2M | $55.2M | Completed | Generating Revenue | |
| 5. PIPE | 10-Oct-2017 | $9.1M | $55.2M | Completed | Generating Revenue |
KalVista Pharmaceuticals Comparisons
Industry
Financing
Details
KalVista Pharmaceuticals Competitors (46)
One of KalVista Pharmaceuticals’s 46 competitors is Rallybio, a Formerly VC-backed company based in New Haven, CT.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Rallybio | Formerly VC-backed | New Haven, CT | ||||
| Crinetics Pharmaceuticals | Formerly VC-backed | San Diego, CA | ||||
| Renova Therapeutics | Venture Capital-Backed | Carlsbad, CA | ||||
| BioMarin Pharmaceutical | Formerly PE-Backed | San Rafael, CA | ||||
| Emmaus Life Sciences | Formerly VC-backed | Torrance, CA |
KalVista Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
KalVista Pharmaceuticals Patents
KalVista Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026003532-A1 | Sebetralstat for the treatment of anxiety associated with hereditary angioedema | Pending | 28-Jun-2024 | ||
| GB-202405497-D0 | Enzyme inhibitors | Inactive | 18-Apr-2024 | ||
| GB-202405499-D0 | Enzyme inhibitors | Inactive | 18-Apr-2024 | ||
| GB-202402729-D0 | Methods for determining amidolytic activity | Inactive | 27-Feb-2024 | ||
| AU-2025220950-A1 | Oral sebetralstat for the treatment of an attack of hereditary angioedema | Pending | 13-Feb-2024 | A61K31/444 |
KalVista Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
KalVista Pharmaceuticals Former Investors (12)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Blackwell Partners | Asset Manager | Minority | ||
| Carbylan Therapeutics | Corporation | Minority | ||
| InterWest Health Partners | Corporate Venture Capital | Minority | ||
| International Biotechnology Trust | Venture Capital | Minority | ||
| Longwood Fund Management | Venture Capital | Minority |
KalVista Pharmaceuticals Investments & Acquisitions (2)
KalVista Pharmaceuticals’s most recent deal was a Merger/Acquisition with Carbylan Therapeutics for . The deal was made on 21-Nov-2016.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Carbylan Therapeutics | 21-Nov-2016 | Merger/Acquisition | Drug Discovery | ||
| Vantia Therapeutics (Kallikrein Inhibitors & Intellectual Property) | 23-Aug-2011 | Corporate Asset Purchase | Buildings and Property |
KalVista Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated March, 31, 2025
37.37 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,221
Rank
Percentile
Pharmaceuticals
Industry
of 903
Rank
Percentile
Pharmaceuticals
Subindustry
of 405
Rank
Percentile
KalVista Pharmaceuticals FAQs
-
When was KalVista Pharmaceuticals founded?
KalVista Pharmaceuticals was founded in 2011.
-
Where is KalVista Pharmaceuticals headquartered?
KalVista Pharmaceuticals is headquartered in Framingham, MA.
-
What is the size of KalVista Pharmaceuticals?
KalVista Pharmaceuticals has 270 total employees.
-
What industry is KalVista Pharmaceuticals in?
KalVista Pharmaceuticals’s primary industry is Drug Discovery.
-
Is KalVista Pharmaceuticals a private or public company?
KalVista Pharmaceuticals is a Private company.
-
What is the current valuation of KalVista Pharmaceuticals?
The current valuation of KalVista Pharmaceuticals is .
-
What is KalVista Pharmaceuticals’s current revenue?
The current revenue for KalVista Pharmaceuticals is .
-
How much funding has KalVista Pharmaceuticals raised over time?
KalVista Pharmaceuticals has raised $380M.
-
Who are KalVista Pharmaceuticals’s investors?
Blackwell Partners, Carbylan Therapeutics, InterWest Health Partners, International Biotechnology Trust, and Longwood Fund Management are 5 of 12 investors who have invested in KalVista Pharmaceuticals.
-
Who are KalVista Pharmaceuticals’s competitors?
Rallybio, Crinetics Pharmaceuticals, Renova Therapeutics, BioMarin Pharmaceutical, and Emmaus Life Sciences are some of the 46 competitors of KalVista Pharmaceuticals.
-
When was KalVista Pharmaceuticals acquired?
KalVista Pharmaceuticals was acquired on 11-Jun-2026.
-
Who acquired KalVista Pharmaceuticals?
KalVista Pharmaceuticals was acquired by Chiesi Farmaceutici.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
